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Abstract
The recently licensed quadrivalent seasonal influenza vaccine (QIV) may provide better protection
than the traditional trivalent influenza vaccine (TIV) as it includes one more influenza B strain.
We developed a Monte Carlo simulation model to determine the economic value of a QIV
compared to the TIV for ten influenza seasons (1999–2009). The addition of the influenza B strain
to convert the TIV into a QIV could result in substantial cost savings to society (median of $3.1
billion) and third party payers (median of $292 million), even when the cost of QIV is
significantly higher
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INTRODUCTION
By including one more influenza B strain than the traditional trivalent influenza vaccine
(TIV), the recently licensed quadrivalent seasonal influenza vaccine (QIV; MedImmune
FluMist Quadrivalent for persons aged 2 to 49 years[1]) may provide better protection for
the population [2–3]. Each year, the TIV contains three influenza strains, A/H1N1, A/H3N2,
and one of two B strains, selected at least 6 months prior to the start of the influenza season
[3–4]. The QIV may be an important advantage since predicting which of the two influenza
B strain lineages, Yamagata and Victoria, will circulate in the following influenza season
has been a continuing challenge and a vaccine with just one B strain may offer little
protection against the other B strain [2–4]. Reed et al. estimated the additional influenza
cases that a QIV may have averted over TIV during the past decade [3]. In this study, we
utilize the results from the Reed et al. study to determine the potential cost-savings the QIV
may provide, which can in turn help guide pricing, adoption, and reimbursement of the QIV.
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MATERIALS AND METHODS
We developed a Monte Carlo simulation model in Microsoft Excel (Microsoft, Redmond,
WA) using a Crystal Ball (Oracle, Redwood City, CA) add-in to determine the economic
value of a QIV compared to the TIV for ten influenza seasons (1999–2009) from the third
party payer and societal perspectives. The third party payer perspective included only the
direct costs of illness (i.e., cost of outpatient visits and hospitalization), while the societal
perspective included direct and indirect costs of illness (i.e., productivity losses due to
missed work and mortality). Table 1 shows our model inputs. All costs were age-stratified
where applicable and in 2012 $US, converted using a 3% discount rate[5].
The age-stratified population (using the following groups: <1, 1–17, 18–44, 45–64, 65–84,
and ≥85 years) for each influenza season came from the US Census Bureau (e.g., the 2008–
2009 influenza season assumed the 2008 US population estimate) [6].
The study by Reed et al. provided the number of all influenza cases, hospitalizations, and
deaths averted each year by vaccinating with a QIV compared to the TIV[3]. The first step
was to separate these numbers into three mutually exclusive categories by age (using the age
distributions from Table 1):
!! Persons who were infected without requiring hospitalization: A symptomatic
person drew from the distribution of days of school or work missed (depending
on age), which would then result in costs of lost patient (or caregiver in the case
of a child) productivity to society (based on wage data from the Bureau of Labor
Statistics assuming an 8-hour work day). A symptomatic person also had a
probability of an outpatient clinic visit, which would result in the cost of a clinic
visit (both perspectives) and four hours of lost productivity (just from the
societal perspective).
!! Those who required hospitalization and survived: A hospitalized person incurred
the cost of an outpatient visit (both perspectives), the cost of a hospitalization
drawn from a distribution in Table 1 (both perspectives), and the lost
productivity during the days of hospitalization (just the societal perspective).
!! Those who were hospitalized and died: A hospitalized person who did not
survive who accrue the additional cost of death and lost lifetime productivity
(just societal perspective), calculated from the expected life expectancy of that
person [7] and the discounted expected value of the person’s remaining lifetime
earnings [8].
The Reed et al. study made several key assumptions that also hold in our study: (1) QIV
would have efficacy against each included strain comparable to the strain included in the
TIV (47–68%), assuming that the added B strain in the QIV would have the same efficacy as
the B strain that was included (2) efficacy would not differ as substantially over different
age strata and influenza strain/lineage; and (3) fewer does of QIV would be produced and its
introduction would be in stages rather than wholesale replacement of TIV. Reed et al. also
used population averages, and therefore did not account for potential differences in age,
influenza strain/lineage, and health impact. Additionally, as the Reed study used vaccine
coverage rates (18–30%) based on prior vaccination target population recommendations for
each particular year, our study does as well.
Probabilistic sensitivity analyses simultaneously varied each parameter throughout their
ranges listed in Table 1. Additional sensitivity analyses varied the price premium of the QIV
vaccine over the TIV vaccine (range: $0–$120). Each simulation involved 5,000 iterations
or trials.
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RESULTS
Table 2 shows expected median cost-savings across the entire United States for the third
party payers and society if the QIV instead of the TIV were used at different price premiums
for the QIV vaccine (i.e., if the QIV cost $5, $15, $30, and $120 more than the TIV). This
would translate to a median of $3.1 billion societal cost-savings (mean: $3.1 billion; 95%
range: $2.8–3.5 billion) and a median of $292 million third party payer costs savings (mean:
$294 million; 95% range: $251–342 million) during the decade if the QIV were used instead
of the TIV and priced equally to the TIV. Raising the price of the QIV over the TIV
decreased the median cost-savings. A higher costing vaccine would still be beneficial in
some seasons, as cost-savings were seen for the QIV up to premiums of $120 for society and
$105 for third party payers. Utilization of QIV becomes less cost-saving as QIV price
premiums surpass $105 for third party payers.
Over the entire decade, 2,684,145 total cases were averted. From the third party payer
perspective, a $120 premium would have saved $11 per case and a $0 premium would have
saved $109 per case across the entire decade (from 1999–2009). Cost-savings per case
across the entire decade from the societal perspective ranged from $1,163 ($0 premium) to
$1,041 ($120 premium). The cost per case tended to increase as premiums decreased,
resulting in less cost-savings.
As there were no cases averted for the 1999–2000 and 2000–2001 influenza seasons, there
was no cost advantage of the QIV. From the third party payer perspective, the 2007–2008
season yielded the highest median cost-savings per case and death averted, even saving costs
with a premium as high as $120 ($2 per case averted and $3,831 per death averted).
Whereas the highest cost-savings per hospitalization averted were found for the 2001–2002
influenza season for all premiums up to $105 (from both perspectives). At higher premiums
it would cost third party payers up to $23–$38 to averted one case, $4,450–$7,332 to averted
one hospitalization, and $45,865–$75,570 to averted one death, for premiums of $105 and
$120 respectively.
DISCUSSION
Adding an additional B strain to the seasonal influenza vaccine could reap substantial cost-
savings for society and third party payers, even if the QIV enjoyed a significant price
premium over TIV. It is not common for a new medical technology, especially one that is a
variation of an existing technology, to immediately generate cost-savings[9]. (Most
technologies require additional costs to result in health benefits.) Such savings may reassure
third party payers of the value of covering a more expensive QIV as they would be likely to
recoup this investment through averting healthcare costs. This in turn could facilitate
adoption and also motivate additional scientists, developers, and manufacturers to enter the
QIV market and investigate the possibility of adding even more strains to the vaccine.
Moreover, the cost-savings could be greater in the coming decade as the Advisory
Committee on Immunization Practices (ACIP) has increased the scope of whom they
recommend should be vaccinated[10], which could in turn increase coverage of the overall
population.
These findings also highlight the difficulty in accurately predicting the circulating influenza
strains for the upcoming influenza season and the cost of inaccurate predictions. For
example, missing on the B strain for the 2007–2008 influenza season seems to have cost
third party payers well over $100 million and society well over $1 billion. This year 29% of
all influenza were influenza B viruses, of which 98% were from the Yamagata lineage,
while the TIV vaccine was manufactured with the Victoria lineage[3]. Although there are
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continuing efforts to improve the accuracy of strain predictions, adding more strains to the
seasonal vaccine could be a promising route.
Currently, only MedImmune’s QIV has FDA approval , but GlaxoSmithKline, Sanofi
Pasteur, and Novartis Vaccines are in various stages of QIV development; their QIV
formulations are expected to reach the market for the 2013–14 influenza season [11].
MedImmune plans to discontinue the current TIV FluMist and offer only the FluMist
Quadrivalent vaccine for the 2013–14 influenza season, where as GlaxoSmithKline and
Sanofi Pasteur plan to introduce their QIV formulations in conjunction with their current
TIV vaccines[11].
Every model is a simplification of real life and cannot account for every possible factor and
outcome[12]. Our results assume that QIV vaccine production could have been high enough
to cover the number of TIV doses administered each year, which should eventually be
possible, but could require an expansion in production capacity to accommodate the
additional strain[2]. Therefore, the realization of cost-savings would depend on the timing of
replacement of TIV with QIV: more slowly for gradual replacement and more near term if
companies such as MedImmune do rapid en masse replacement[11]. Expansion of vaccine
manufacturing capacity since the 2005–06 season and the inception production methods
(e.g., cell culture) could further foster industry’s ability to replace TIV[11]. On the other
hand, additional limitations may make our estimates of the cost-savings conservative. Our
study used the adjusted vaccine production numbers from Reed et al.; using less
conservative numbers would increase QIV’s cost-savings by averting more influenza
outcomes. Current and future broader target population recommendations may further
enhance the economic value of the QIV. It also did not account for over-the-counter self-
treatment and all additional costs from medical problems (e.g., congestive heart failure or
pulmonary disease exacerbations) that may be precipitated by influenza. Our model did not
include any potential adverse events since reported ones are infrequent and relatively minor
(e.g., runny nose, nasal congestion, sore throat)[1] and evidence does not suggest a higher
rate than TIV. Our study draws from the Reed et al. study and therefore is subject to its
limitations and assumptions.
In conclusion, the addition of the influenza B strain to convert the TIV into a QIV could
result in substantial cost-savings to society and third party payers, even when the cost of
QIV is significantly higher, information which could be useful to insurers (e.g., coverage
decisions), manufacturers (e.g., production and pricing), developers (e.g., prioritizing
research), and policy makers (e.g., adoption).
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Highlights
We model the economic value of a QIV compared to the TIV for ten influenza seasons
QIV provided cost savings during the decade if used instead of the TIV
A higher costing (up to $120) vaccine would still be beneficial in some seasons
Adding an additional B strain could reap substantial savings
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Table 1
Model Input Parameters
Parameter Mean or
Median
Standard Deviation
or Range
Source
Median Hourly Wage 17.26 [8]
Missed Work Days 3.2 1.5 – 4.9 [13]
Missed School Days 2.54 [14]
Probability of Outpatient Visit
 <1 year old 45.5 26 – 65 [15]
 1 – 17 years old 31.8 20 – 44 [15]
 18 to 64 years old 31.3 29 – 34 [15]
 65 years and older 62 57 – 67 [15]
Cost of Outpatient Visit
 <1 year old 76.17 [16]
 1 – 17 years old 81.47 [16]
 18 – 64 years old 102.51 [16]
 65 – 84 years old 93.46 [17]
 85 years and older 90.04 [17]
Duration of Outpatient Visit (hours) 4 Assumption
Cost of Hospitalization
 <1 year old 4,221.24 385.29 [18]
 1 – 17 years old 6,119.74 751.64 [18]
 18 – 44 years old 10,517.29 444.16 [18]
 44 – 64 years old 11,372.51 403.39 [18]
 65 – 84 years old 9,502.05 387.78 [18]
 85 years and older 8,545.11 407.72 [18]
Productivity Loss due to Mortality
 <1 year old 1,461,022 [7–8]
 1 – 17 years old 1,413,302 [7–8]
 18 – 44 years old 1,226,143 [7–8]
 44 – 64 years old 889,374 [7–8]
 65 – 84 years old 516,093 [7–8]
 85 years and older 222,244 [7–8]
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Table 2
Cost-savings [median (95% range), $US in millions] of the additional benefits of QIV vs. TIV over ten
influenza seasons to third party payers and society
Influenza
Season
Price Premium of QIV over TIV
$5 $15 $30 $120
Cost-Savings to Third Party Payers [median (95% range)]
1999–2000a None None None None
2000–2001a None None None None
2001–2002 21.1 (18.3–24.3) 18.4 (15.6–21.6) 14.2 (11.5–17.5) 10.4 (7.0–13.0)
2002–2003 0.2 (0.17–0.23) 0.17 (0.15–0.21) 0.14 (0.11–0.17) 0.06 (0.03–0.09)
2003–2004 2.2 (1.8–2.5) 1.9 (1.6–2.3) 1.6 (1.3–2.0) 0.2 (0.19–0.51)
2004–2005 29 (24.9–33.6) 25.7 (21.6–30.4) 20.7 (16.7–25.4) 8.9 (4.0–12.8)
2005–2006 29.2 (25.2–33.8) 25.7 (21.7–30.4) 20.5 (16.5–25.1) 11 (6.2–14.8)
2006–2007 6.3 (5.3–7.4) 5.7 (4.7–6.8) 4.8 (3.9–5.9) 0.42 (0.73–1.3)
2007–2008 155.8 (131.7–183.8) 142.3 (118.0–170.5) 122.1 (98.4–151.1) 2.5 (31.9–20.7)
2008–2009 35.8 (30.5–42.1) 32.5 (27.1–38.8) 27.5 (22.2–34.0) 2.0 (4.6–7.3)
Decade Total 279.5 (238.1 – 327.8) 252.5 (210.5–301.1) 211.5 (170.7–261.4) 30.4 (20.2–70.4)
Per Year 28 (23.8 – 32.8) 25.2 (21.0–30.1) 21.2 (17.1–26.1) 3.0 (2.0–7.0)
Cost-Savings to Society [median (95% range)]
1999–2000a None None None None
2000–2001a None None None None
2001–2002 307.2 (273.4–340.9) 304.5 (270.4–338.2) 300.3 (266.5–333.2) 275.2 (242.3–309.9)
2002–2003 2.4 (2.1–2.7) 2.4 (2.1–2.7) 2.4 (2.1–2.6) 2.1 (1.9–2.4)
2003–2004 23.2 (20.7–25.8) 23 (20.5–25.5) 22.7 (20.2–25.2) 20.8 (18.3–23.4)
2004–2005 371.2 (330.3–411.9) 367.9 (326.6–408.8) 363 (322.0–403.0) 332.7 (292.7–374.8)
2005–2006 392.3 (348.8–435.8) 388.9 (344.9–432.5) 383.5 (339.9–426.3) 351.5 (308.9–396.3)
2006–2007 66.7 (59.4–74.0) 66.2 (58.8–73.4) 65.3 (58.0–72.4) 59.9 (52.8–67.5)
2007–2008 1,536.8 (1,370–1,704) 1,524.30 (1,355–1,690) 1,503.7 (1,335–1,668) 1381.9 (1216.3–1554.4)
2008–2009 408.6 (367.1–450.0) 405.4 (363.5–446.6) 400.3 (358.9–440.9) 370.1 (329.5–412.9)
Decade Total 3,108.8 (2,771–3,446) 3,082.4 (2,742 –3,419) 3,040.9 (2,704–3,372) 2,793.9 (2,463.3–3,142.1)
Per Year 310.9 (277.1–344.6) 308.2 (274.2–341.9) 304.1 (270.4–337.2) 279.4 (246.3–314.2)
a
The QIV did not provide any appreciable cost-savings as the influenza B strain for the TIV matched with the circulating strain[3]
Note: Bold values imply costs
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